Distinct clinical outcomes of non-small cell lung cancer patients with Epidermal Growth Factor Receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: Non-responders versus responders

研究成果: 雜誌貢獻文章同行評審

8 引文 斯高帕斯(Scopus)

摘要

Introduction: Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in patients with non-small cell lung cancers (NSCLC) harboring EGFR mutations. However, a subset of this population doesn't respond to EGFR-TKI treatment. Therefore, the present study aimed to elucidate survival outcome in NSCLC EGFR-mutant patients who were treated with EGFR TKIs. Methods: Among the 580 consecutive NSCLC patients who were treated at our facility between 2008 and 2012, a total of 124 treatment-naïve, advanced NSCLC, EGFR-mutant patients treated with EGFR TKIs were identified and grouped into nonresponders and responders for analyses. Results: Of 124 patients, 104 (84%) responded to treatment, and 20 (16%) did not; and the overall median PFS was 9.0 months. Notably, the PFS, overall survival (OS) and survival rates were significantly unfavorable in non-responders (1.8 vs. 10.3 months, hazard ratio (HR) = 29.2, 95% confidence interval (CI), 13.48-63.26, P
原文英語
文章編號e83266
期刊PLoS One
8
發行號12
DOIs
出版狀態已發佈 - 十二月 23 2013

ASJC Scopus subject areas

  • 農業與生物科學 (全部)
  • 生物化學、遺傳與分子生物學 (全部)
  • 醫藥 (全部)

指紋

深入研究「Distinct clinical outcomes of non-small cell lung cancer patients with Epidermal Growth Factor Receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: Non-responders versus responders」主題。共同形成了獨特的指紋。

引用此